GleamWall
中文EN

SUPN Supernus, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1625297 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY16.3%
TTM net income YoY251.6%
TTM EPS YoY253.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin85.0%
Operating margin40.6%
Net margin32.8%
FCF margin2.3%
EBITDA margin41.1%

Returns

ROE—
ROA32.8%
ROIC (approx.)—
Asset turnover1.00x

Leverage & solvency

Liabilities / assets104.5%
Debt / equity—
Current ratio0.61x
Interest coverage32.82x

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio25.8%
Payout ratio—
Capex / revenue4.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.24B$1.19B
Cost of revenue$246.00M$231.00M
Gross profit$994.00M$957.00M
R&D expense$97.00M$107.00M
SG&A expense$634.00M$612.00M
Operating income$262.00M$38.00M
Interest expense$45.00M$41.00M
Pretax income$239.00M$20.00M
Income tax$29.00M$13.00M
Net income$210.00M$7.00M
EBITDA$272.00M$54.00M
EPS (basic)1.680.05
EPS (diluted)1.640.05
Weighted avg. shares (diluted)128.00M133.00M
Balance sheet
Cash & equivalents$195.00M$319.00M
Short-term investments$0$1.00M
Receivables$253.00M$254.00M
Inventory$153.00M$167.00M
Current assets$652.00M$827.00M
PP&E, net$144.00M$100.00M
Goodwill$2.00M$2.00M
Total assets$1.20B$1.32B
Current liabilities$914.00M$924.00M
Short-term debt$29.00M$18.00M
Long-term debt$290.00M$315.00M
Total debt$319.00M$333.00M
Total liabilities$1.30B$1.65B
Shareholders' equity-$98.00M-$337.00M
Net debt$124.00M$14.00M
Cash flow statement
Operating cash flow-$27.00M$36.00M
Capital expenditure$66.00M$29.00M
Free cash flow-$93.00M$7.00M
Investing cash flow-$66.00M$69.00M
Financing cash flow-$30.00M-$102.00M
Depreciation & amortization$10.00M$16.00M
Stock-based compensation$26.00M$24.00M
Share buybacks$11.00M$173.00M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.